Thursday, November 21, 2024
11/21/2024
Abstract The Division of Clinical Pharmacology, Toxicology, and Therapeutic Innovation at Children’s Mercy Hospital (CMH) in Kansas City, offers one of the largest, most diverse, Pediatric Clinical Pharmacology post-doctoral training programs in the U.S. It is constituted by 20 faculty including 1) clinicians cross-trained in Allergy/ Asthma/Immunology, Behavioral Medicine, Cardiology, Environmental/Occupational Health, Gastroenterology, Hematology/Oncology, Infectious Diseases, Maternal/Fetal Medicine, Neonatology, Nephrology, Nursing, Pharmacy, Rehabilitation Medicine, and Toxicology, along with 2) basic/translational scientists with experience in analytical chemistry, genetics, genomics, in vitro biotransformation, and molecular biology. Affiliated faculty contribute additional expertise in the areas of Bioethics, Bioinformatics, Health Outcomes, and Pharmaco- epidemiology. The program has made substantial contributions in the areas of pharmacogenetics, pharmaco- metrics, and early phase clinical trial design. The program combines robust didactic and experiential training in pharmacogenetics/genomics, metabolomics, pharmacometrics, pharmacoepidemiology, drug development, and the responsible conduct of research. It also offers unique elective opportunities dedicated to pediatric PBPK-based modeling and simulation (Simcyp/Certara), pediatric regulatory review and approval (FDA), bioinformatics (PharmGKB), Formulary management (CMH/Medicaid), and adult pharmacology (Mayo). Two independent Masters programs offered by affiliated medical schools round out the academic program at CMH. All teaching is accomplished by faculty with significant research experience in their respective subject areas. Trainees affiliate with the program for a minimum of three years; the first two years in Clinical Pharmacology are blended with the second and third years of their subspecialty training and their third year is dedicated to clinical pharmacology. Under the direction of a junior mentor, a senior mentor, and a scholarship oversight committee, fellows complete both a clinical and translational research project, produce several publications/ presentations, compete for a minimum of one research grant, and develop a plan to transition to independence prior to graduation. Quality is continually assured by a robust evaluation strategy and diversity is supported by a comprehensive recruitment strategy. Since its inception, the program at CMH has trained 24 pediatric clinical pharmacology fellows (17 pediatricians, 6 pharmacists, 1 nurse; 14 female, 2 African American, 1 Hispanic, 1 Native-American, 3 Asian) who during their fellowship period have collectively delivered 118 scientific presentations, prepared 102 peer-reviewed manuscripts and successfully competed for over $1,500,000 in intramural and extramural funding. The program is one of only three American Board of Clinical Pharmacology accredited training programs dedicated solely to Pediatric Clinical Pharmacology and its longstanding record of excellence provides applicants with unparalleled training in the discipline.
HHS’ Tracking Accountability in Government Grants System (TAGGS) website provides access to detailed descriptions of grants, loans, aggregated direct payments and other types of financial assistance awarded by the HHS Operating Divisions (OPDIVs) and the Office of the Secretary Staff Divisions (STAFFDIVs).
